Approval · Notice of Compliance 28676 · 2022
EVUSHELD: Notice of Compliance 28676
Issued July 28, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28676
- Date
- July 28, 2022
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a new drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EVUSHELD | Not yet assigned | — |
Medicinal ingredients
- TIXAGEVIMAB 150 MG per 1.5ML
- CILGAVIMAB 150 MG per 1.5ML